MIT Develops Injectable 'Satellite Livers'

Scientists at the Massachusetts Institute of Technology (MIT), led by bioengineer Sangeeta Bhatia and including Vardhman Kumar, have developed injectable 'satellite livers' to treat severe liver disease. These miniature engineered tissues, composed of liver cells (hepatocytes) and hydrogel microspheres, can be delivered via syringe to support failing liver functions. Early animal studies in mice showed the grafts remained functional for at least eight weeks, producing essential proteins and enzymes. This technology could serve as a temporary bridge to transplantation or a long-term therapy, offering an alternative to major surgery. The team collaborated with a specialist from the Koch Institute for Integrative Cancer Research on ultrasound-guided injection techniques. Future work includes improving graft longevity and exploring immune evasion strategies, potentially revolutionizing treatment for millions worldwide.